RxDoctor Payments Data

Misti Dixon McNees, APRN

Family · Cynthiana, KYNPI 1922551142

Payments from drug & device makers

$1,684in general payments, 2019–2025

Across 90 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$256
  • AbbVie$251
  • Merck$152
  • Sunovion Pharmaceuticals Inc.$144
  • Biohaven Pharmaceutical Holding Company Ltd.$141
  • Sumitomo Pharma America, Inc.$79
  • plus $661 from 22 others

What the payments were for

  • Food & beverage$1,684100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,684 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$38,994
Medicare patients
157
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin112$56,601
EliquisApixaban50$38,864
OzempicSemaglutide42$38,646
GemtesaVibegron51$26,108
TradjentaLinagliptin62$18,250
JanuviaSitagliptin Phosphate22$16,418
LinzessLinaclotide22$15,093
Breo ElliptaFluticasone/Vilanterol13$9,670
MounjaroTirzepatide17$8,693
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,582
Bydureon BciseExenatide Microspheres26$7,484
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,546
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$4,241
LivaloPitavastatin Calcium26$4,217
XareltoRivaroxaban12$3,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$15$74,851174 claims
PfizerEliquis$18$38,86450 claims
Novo NordiskOzempic$256$38,64642 claims
Sumitomo Pharma America, Inc.Gemtesa$79$26,10851 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$64$22,79838 claims
MerckJanuvia$152$16,41822 claims
AbbVieLinzess$251$15,09322 claims
Lilly USA, LLCMounjaro$57$8,69317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Cynthiana

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →